PL385586A1 - Nowe analogi insuliny o przedłużonym działaniu - Google Patents
Nowe analogi insuliny o przedłużonym działaniuInfo
- Publication number
- PL385586A1 PL385586A1 PL385586A PL38558608A PL385586A1 PL 385586 A1 PL385586 A1 PL 385586A1 PL 385586 A PL385586 A PL 385586A PL 38558608 A PL38558608 A PL 38558608A PL 385586 A1 PL385586 A1 PL 385586A1
- Authority
- PL
- Poland
- Prior art keywords
- insulin analogues
- release insulin
- new slow
- new
- slow
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
- 230000001851 biosynthetic effect Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
Ujawniono nowe biosyntetyczne analogi rekombinowanej insuliny ludzkiej o przedłużonym działaniu terapeutycznym, które mogą znaleźć zastosowanie w profilaktyce i terapii cukrzycy.
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL385586A PL219335B1 (pl) | 2008-07-04 | 2008-07-04 | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna |
| PCT/PL2009/050010 WO2010002283A2 (en) | 2008-07-04 | 2009-07-04 | New insulin analogues of prolonged activity |
| EA201170149A EA023559B1 (ru) | 2008-07-04 | 2009-07-04 | Аналоги инсулина человека с пролонгированной терапевтической активностью, стабильные в кислой среде |
| EP11003008.7A EP2371853B1 (en) | 2008-07-04 | 2009-07-04 | Insulin derivatives or its pharmaceutically acceptable salt, pharmaceutical composition, use of insulin derivative or its pharmaceutically acceptable salt and method of treatment |
| EP09773816A EP2321344A2 (en) | 2008-07-04 | 2009-07-04 | New insulin analogues of prolonged activity |
| JP2011516197A JP2011526886A (ja) | 2008-07-04 | 2009-07-04 | 持効型活性を有する新規インスリン類似体 |
| PL11003008T PL2371853T3 (pl) | 2008-07-04 | 2009-07-04 | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, kompozycja farmaceutyczna, zastosowanie pochodnej insuliny lub jej farmaceutycznie dopuszczalnej soli oraz sposób leczenia |
| CN2009801261044A CN102083855A (zh) | 2008-07-04 | 2009-07-04 | 活性延长的新胰岛素类似物 |
| CA2729938A CA2729938C (en) | 2008-07-04 | 2009-07-04 | New insulin analogues of prolonged activity |
| US13/002,520 US8618048B2 (en) | 2008-07-04 | 2009-07-04 | Insulin analogues of prolonged activity |
| US14/090,496 US20140121353A1 (en) | 2008-07-04 | 2013-11-26 | Insulin analogues of prolonged activity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL385586A PL219335B1 (pl) | 2008-07-04 | 2008-07-04 | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL385586A1 true PL385586A1 (pl) | 2010-01-18 |
| PL219335B1 PL219335B1 (pl) | 2015-04-30 |
Family
ID=41130257
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL385586A PL219335B1 (pl) | 2008-07-04 | 2008-07-04 | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna |
| PL11003008T PL2371853T3 (pl) | 2008-07-04 | 2009-07-04 | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, kompozycja farmaceutyczna, zastosowanie pochodnej insuliny lub jej farmaceutycznie dopuszczalnej soli oraz sposób leczenia |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11003008T PL2371853T3 (pl) | 2008-07-04 | 2009-07-04 | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, kompozycja farmaceutyczna, zastosowanie pochodnej insuliny lub jej farmaceutycznie dopuszczalnej soli oraz sposób leczenia |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8618048B2 (pl) |
| EP (2) | EP2371853B1 (pl) |
| JP (1) | JP2011526886A (pl) |
| CN (1) | CN102083855A (pl) |
| CA (1) | CA2729938C (pl) |
| EA (1) | EA023559B1 (pl) |
| PL (2) | PL219335B1 (pl) |
| WO (1) | WO2010002283A2 (pl) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10100098B2 (en) | 2006-12-13 | 2018-10-16 | Stelis Biopharma Private Limited | Insulin production methods and proinsulin constructs |
| JP5635529B2 (ja) | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| NZ593813A (en) | 2008-12-15 | 2013-02-22 | Zealand Pharma As | Glucagon analogues |
| JP5635531B2 (ja) | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| WO2010070252A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| ME02220B (me) | 2009-07-13 | 2016-02-20 | Zealand Pharma As | Analozi acilovanog glukagona |
| AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
| EP2585482B1 (en) | 2010-06-24 | 2019-03-27 | Zealand Pharma A/S | Glucagon analogues |
| MA34913B1 (fr) | 2011-01-20 | 2014-02-01 | Zealand Pharma As | Combinaison d'analogues du glucagon acylé à des analogues d'insuline |
| WO2012115638A1 (en) * | 2011-02-23 | 2012-08-30 | Elona Biotechnologies | Glargine proinsulin compositions and methods of producing glargine insulin analogs therefrom |
| WO2013164483A1 (en) | 2012-05-03 | 2013-11-07 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| PL222975B1 (pl) * | 2012-05-23 | 2016-09-30 | Inst Biotechnologii I Antybiotyków | Analog insuliny lub jego farmaceutycznie dopuszczalna sól, kompozycja farmaceutyczna o przedłużonym działaniu terapeutycznym oraz zastosowanie analogu insuliny |
| US9624287B2 (en) | 2012-07-17 | 2017-04-18 | Case Western Reserve University | O-linked carbohydrate-modified insulin analogues |
| DK2877200T3 (da) * | 2012-07-17 | 2019-08-12 | Univ Case Western Reserve | O-bundne carbonhydratmodificerede insulinanaloger |
| MY170671A (en) | 2012-07-23 | 2019-08-26 | Zealand Pharma As | Glucagon analogues |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| JP2016505627A (ja) * | 2013-01-15 | 2016-02-25 | フェーズバイオ ファーマシューティカルズ，インコーポレイテッド | 治療剤、組成物、および血糖コントロールのための方法 |
| WO2014122653A1 (en) * | 2013-02-07 | 2014-08-14 | Valin Technologies Ltd. | Process for preparing insulin |
| CN103981243A (zh) * | 2013-02-07 | 2014-08-13 | 华凌科技有限公司 | 胰岛素的制备方法 |
| CN103981242A (zh) * | 2013-02-07 | 2014-08-13 | 华凌科技有限公司 | 胰岛素的制备方法 |
| WO2014122651A1 (en) * | 2013-02-07 | 2014-08-14 | Valin Technologies Ltd. | Process for preparing insulin |
| SI3057984T1 (sl) | 2013-10-17 | 2018-10-30 | Zealand Pharma A/S | Acilirani glukagonski analogi |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| EA035688B1 (ru) | 2013-11-06 | 2020-07-27 | Зилэнд Фарма А/С | Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip |
| US10093713B2 (en) | 2013-11-06 | 2018-10-09 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
| TWI705973B (zh) | 2014-10-29 | 2020-10-01 | 丹麥商西蘭製藥公司 | Ｇｉｐ促效劑化合物及方法 |
| TWI707867B (zh) | 2015-04-16 | 2020-10-21 | 丹麥商西蘭製藥公司 | 醯化之昇糖素類似物 |
| PL239062B1 (pl) * | 2016-01-22 | 2021-11-02 | Inst Biotechnologii I Antybiotykow | Sposób wytwarzania insuliny i jej pochodnych |
| CA3294636A1 (en) * | 2016-11-21 | 2026-02-10 | Case Western Reserve University | Rapid-acting insulin analogues of enhanced stability |
| KR102666154B1 (ko) * | 2018-08-08 | 2024-05-20 | 주식회사 대웅제약 | 지속형 인슐린 아날로그 및 그 복합체 |
| SG11202106168VA (en) * | 2018-12-11 | 2021-07-29 | Sanofi Sa | Insulin analogs having reduced insulin receptor binding affinity |
| EP4048686A4 (en) * | 2019-10-24 | 2024-01-03 | University Of Utah Research Foundation | NEW MINI INSULIN WITH EXTENDED C-TERMINAL A-CHAIN |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3327709A1 (de) * | 1983-07-29 | 1985-02-07 | Hoechst Ag, 6230 Frankfurt | Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung |
| US5434247A (en) * | 1986-10-10 | 1995-07-18 | Board Of Regents, The University Of Texas System | Peptides for inducing monocyte cytotoxicity in diagnostics |
| US5135736A (en) * | 1988-08-15 | 1992-08-04 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
| DE3837825A1 (de) | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
| DE3844211A1 (de) | 1988-12-29 | 1990-07-05 | Hoechst Ag | Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
| SG44748A1 (en) * | 1991-12-18 | 1997-12-19 | Hoechst Ag | Process for obtaining insulin-containing solutions |
| HU220357B (hu) | 1992-02-28 | 2001-12-28 | Autoimmune Inc. | Eljárás és készítmények autoimmun betegségek kezelésére bystander antigén alkalmazásával |
| DE4405179A1 (de) * | 1994-02-18 | 1995-08-24 | Hoechst Ag | Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken |
| DE19652713C2 (de) | 1996-12-18 | 2001-11-22 | Aventis Pharma Gmbh | Verfahren zur Reinigung von Insulin und Insulinderivaten durch Chromatographie an stark saurem Kationenaustauscher |
| DE19825447A1 (de) | 1998-06-06 | 1999-12-09 | Hoechst Marion Roussel De Gmbh | Neue Insulinanaloga mit erhöhter Zinkbildung |
| PT1141014E (pt) * | 1999-01-06 | 2005-04-29 | Genentech Inc | Variante mutante do factor de crescimento semelhante a insulina (igf-i) |
| US6777207B2 (en) | 1999-12-29 | 2004-08-17 | Novo Nordisk A/S | Method for making insulin precursors and insulin precursor analogues having improved fermentation yield in yeast |
| ES2313018T3 (es) * | 2003-06-17 | 2009-03-01 | Sembiosys Genetics Inc. | Procedimiento de produccion de insulina en plantas. |
| PL213561B1 (pl) | 2004-01-09 | 2013-03-29 | Inst Biotechnologii I Antybiotykow | Sposób otrzymywania plazmidu, plazmid oraz zastosowania |
| US7893197B2 (en) * | 2004-08-25 | 2011-02-22 | Janssen Pharmaceutica N.V. | Relaxin-3 chimeric polypeptides and their preparation and use |
| EP2801366A3 (en) * | 2004-09-02 | 2015-04-29 | Cognosci, Inc. | Improved apo E analogs and methods for their use |
| PL373543A1 (pl) * | 2005-03-10 | 2006-09-18 | Instytut Biotechnologii i Antybiotyków | Kompozycja farmaceutyczna zawierająca biosyntetyczny analog insuliny ludzkiej, oraz jej zastosowanie w terapii cukrzycy |
| EP2371850A3 (en) * | 2005-06-17 | 2012-08-01 | Mannkind Corporation | Epitope analogues |
| DE102005051366A1 (de) * | 2005-10-25 | 2007-04-26 | Degussa Gmbh | Drug Delivery Systeme |
| EP1996709A2 (en) * | 2006-03-13 | 2008-12-03 | Novo Nordisk A/S | Acylated single chain insulin |
| EP2049149B1 (en) * | 2006-07-31 | 2015-04-15 | Novo Nordisk A/S | Pegylated extended insulins |
| WO2008049711A1 (en) * | 2006-10-27 | 2008-05-02 | Novo Nordisk A/S | Peptide extended insulins |
-
2008
- 2008-07-04 PL PL385586A patent/PL219335B1/pl unknown
-
2009
- 2009-07-04 WO PCT/PL2009/050010 patent/WO2010002283A2/en not_active Ceased
- 2009-07-04 EA EA201170149A patent/EA023559B1/ru not_active IP Right Cessation
- 2009-07-04 CA CA2729938A patent/CA2729938C/en not_active Expired - Fee Related
- 2009-07-04 EP EP11003008.7A patent/EP2371853B1/en not_active Not-in-force
- 2009-07-04 JP JP2011516197A patent/JP2011526886A/ja active Pending
- 2009-07-04 CN CN2009801261044A patent/CN102083855A/zh active Pending
- 2009-07-04 US US13/002,520 patent/US8618048B2/en not_active Expired - Fee Related
- 2009-07-04 EP EP09773816A patent/EP2321344A2/en not_active Withdrawn
- 2009-07-04 PL PL11003008T patent/PL2371853T3/pl unknown
-
2013
- 2013-11-26 US US14/090,496 patent/US20140121353A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2729938A1 (en) | 2010-01-07 |
| US20110136736A1 (en) | 2011-06-09 |
| EA023559B1 (ru) | 2016-06-30 |
| WO2010002283A2 (en) | 2010-01-07 |
| CA2729938C (en) | 2018-11-06 |
| PL219335B1 (pl) | 2015-04-30 |
| CN102083855A (zh) | 2011-06-01 |
| EP2371853B1 (en) | 2017-09-13 |
| US8618048B2 (en) | 2013-12-31 |
| EA201170149A1 (ru) | 2011-06-30 |
| US20140121353A1 (en) | 2014-05-01 |
| EP2321344A2 (en) | 2011-05-18 |
| WO2010002283A3 (en) | 2010-04-29 |
| WO2010002283A9 (en) | 2011-01-20 |
| EP2371853A3 (en) | 2012-10-03 |
| JP2011526886A (ja) | 2011-10-20 |
| EP2371853A2 (en) | 2011-10-05 |
| PL2371853T3 (pl) | 2018-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL385586A1 (pl) | Nowe analogi insuliny o przedłużonym działaniu | |
| EA201991014A1 (ru) | Лечение диабета | |
| MX2013004406A (es) | Tratamiento de diabetes mellitus usando inyecciones de insulina administradas con intervalos variables de inyeccion. | |
| PH12018500767A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| IL201479A (en) | Use of tapentadol for the preparation of pain medication | |
| PH12013500808A1 (en) | Pharmaceutical combinations for the treatment of metabolic disorders | |
| MX2008013304A (es) | Compuestos de peptido 1 tipo glucagon. | |
| EA201101117A1 (ru) | Ингибиторы дпп-4 для лечения диабета у детей | |
| GB2465677B (en) | Non-systemic delivery of satiogens for use in the treatment of obesity and/or diabetes | |
| MY165651A (en) | Use of ultrarapid acting insulin | |
| EA201200793A1 (ru) | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин | |
| TN2011000176A1 (en) | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug | |
| MX2014015423A (es) | Analogos de peptido de exedina-4. | |
| NZ719520A (en) | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway | |
| LT2013018A (lt) | Farmacinė kompozicija, skirta gydyti diabetą ir metabolinius sutrikimus | |
| MX347372B (es) | Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa. | |
| EP2566502A4 (en) | METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION | |
| EP1997503A3 (en) | Treatment of melanoma with alpha thymosin peptides | |
| UA112981C2 (uk) | Варіант людського gdnf | |
| WO2010075444A3 (en) | Nasal formulations of metoclopramide | |
| MX2014001271A (es) | Tratamiento de diabetes de tipo 2 con fty720. | |
| EA202090141A1 (ru) | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин | |
| UA106357C2 (ru) | Лечение диабета у пациентов, у которых наблюдается недостаточный гликемический контроль, несмотря на лечение пероральным или непероральным противодиабетическим лекарственным средством | |
| TN2013000187A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| MX2009002091A (es) | Metodos para reducir las concentraciones de glucosa. |